T cell engagers confront new rules in autoimmunity

T cell engagers are rapidly moving into autoimmune diseases, but development will be more complicated than simply using approved cancer therapies in autoimmune settings at the same doses. The biotechs leading the modality into the clinic now face a central challenge: defining how best to use bispecific antibodies in B cell-driven autoimmune diseases.

As the first developers begin to define dosing strategies, a divide is emerging: using these drugs to trigger a deep, short-course immune reset or to deliver a safer, more controllable form of B cell suppression...